Yes, it's possible. In recent years, NMN nicotinamide mononucleotide powder has gradually become a raw material of interest in the nutrition industry due to its relevance to cellular energy metabolism, aging research, and health management. In addition to the human dietary supplement market, some pet brands have also begun exploring the application of NMN bulk powder in dog nutritional products.
Can Dogs Have NMN?
Based on existing publicly available research and market application data, dogs can ingest NMN nicotinamide mononucleotide powder. However, its use requires three prerequisites: a scientifically designed dosage, a professional health assessment for each dog, and a rigorous quality control system. Several limiting factors should also be considered.
• First, NMN is not an essential nutrient in traditional dog food.
A dog's basic nutritional needs include protein, fat, carbohydrates, vitamins, and minerals. Pure NMN powder is a functional molecule. Its role is to regulate metabolic pathways rather than provide basic nutritional support.
• Second, the number of NMN clinical studies in pets remains limited.
Published dog studies currently include a subacute toxicity study in beagles (14 days, 1340 mg/day), a randomized controlled trial on cognitive function in older dogs (3 months, compound formulation), and an in vitro mechanism study using dog intestinal epithelial cells. Compared with the large amount of research in humans, dog data remains insufficient. Limitations include small sample sizes, short intervention periods, and limited endpoint diversity.
• Third, individual differences
Individual differences among NMN for dogs can significantly affect the applicability and safety. Different breeds vary in body weight, metabolic enzyme activity, and drug clearance rates. Age also affects the decline of endogenous NAD+ levels in older dogs. Health status, especially liver and kidney function, directly influences the metabolism and excretion of NMN pure powder.
• Fourth, long-term use data is still limited.
Current studies have intervention periods of up to six months. Safety data covering the full lifespan of dogs is not yet available.
Is There an NMN Metabolic Mechanism In Dogs?
Dogs belong to the order Carnivora and the family Canidae. Their NAD+ metabolic pathways are highly conserved compared with those of other mammals. Multiple endogenous pathways for NAD+ synthesis exist in dogs. These include the de novo synthesis pathway using tryptophan as a precursor, the Preiss-Handler pathway using niacin as a precursor, and the salvage pathway using nicotinamide as a precursor. In the salvage pathway, nicotinamide is converted into NMN by nicotinamide phosphoribosyltransferase (NAMPT). NMN nicotinamide mononucleotide powder is then converted into NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT). Existing studies support the expression of these enzyme systems in dog tissues.
Therefore, in theory, exogenously supplemented NMN nicotinamide mononucleotide powder can be recognized and converted into NAD+ by the endogenous enzyme systems of dogs. This conclusion is based on the conserved nature of metabolic pathways across mammals and published in vitro studies on dog intestinal epithelial cells. These studies have shown that exogenous NMN can be taken up by dog cells and can produce downstream biological effects. These effects include increased NAD+ levels, enhanced antioxidant enzyme activity, and reduced expression of inflammation-related genes.
However, two important points should be clarified.
First, the presence of a metabolic mechanism does not prove the safety and efficacy of long-term supplementation. Metabolic capability only indicates that NMN nicotinamide mononucleotide powder can be utilized by the body. The safe dosage range, long-term toxicological outcomes, and contraindications under specific physiological conditions-such as hepatic or renal insufficiency, pregnancy, and early developmental stages-still require validation through dog-specific toxicology and pharmacokinetic studies.
Second, the development of pet nutritional products must be based on research specific to the target species. Human research data cannot be directly NMN nicotinamide mononucleotide powder applied to dogs. Different species vary in metabolic rates, tissue distribution, excretion pathways, and biological sensitivity. Dosages established as safe in human studies must be adjusted and verified through dog dose-finding studies.
What is NMN Used For in the Pet Field?
From a product development perspective, NMN nicotinamide mononucleotide powder applications are not limited to single-function supplements. It also has the potential to enter multiple niche markets.
• Elderly Dog Nutrition Products
Globally, the life expectancy of companion dogs continues to increase. The proportion of senior dogs in the pet population is also rising each year. Nutritional products for this group can focus on three key areas: vitality support formulas to improve energy metabolism, cognitive support formulas to maintain neurological function, and long-term health management formulas for systematic anti-aging nutritional intervention. As a precursor of NAD+, NMN nicotinamide mononucleotide powder can be explored as a functional ingredient across these application areas.
• Functional Pet Snacks
In recent years, the pet snack market has shown a strong trend toward functional products. Common product forms include nutritional soft chews, freeze-dried granules, nutrition bars, and functional sandwich snacks. NMN nicotinamide mononucleotide powder can be combined with other active ingredients, such as fish oil, probiotics, and antioxidants, to create multi-functional snack formulations. This category places high demands on palatability and dosage form stability. Therefore, systematic validation is required during product development.
• Pet Nutritional Supplements
This category includes powders, capsules, tablets, liquid products, and granules. Compared with staple foods and treats, nutritional supplements are more suitable for high-value ingredients. They also provide greater formulation flexibility and more precise dosage control. NMN nicotinamide mononucleotide powder can be added as a single ingredient or used in combination formulas. This approach supports dosage customization and personalized use recommendations.
• High-End Pet Prescription Nutrition
As precision nutrition becomes more important in the pet healthcare industry, personalized formulations are becoming a growing trend. Key applications include comprehensive management formulas for senior dogs, metabolic support formulas for working and active dogs, bone, joint, and cardiovascular support formulas for large breeds, and medical nutrition products for premium pet hospitals. NMN nicotinamide mononucleotide powder, may offer further development opportunities in these applications. However, more breed-specific research data is needed.
As a professional NMN powder supplier, Guanjie Biotech focuses on the research and development of innovative functional ingredients and strict quality control systems. The company is committed to providing stable and high-quality raw material solutions to global customers. Guanjie Biotech serves customers in more than 100 countries and regions. We can provide bulk NMN supply, customized specification development, formulation support, application technology assistance, and quality documentation support based on different customer requirements. As the pet nutrition industry moves toward precision and functional products, high-quality NMN nicotinamide mononucleotide powder may become an important component of premium pet health solutions.
Conclusion:
NMN powder has potential applications in pet anti-aging, cognitive support, and metabolic health. However, dog research is still at an early stage. Long-term safety data and standardized dosage guidelines have not yet been fully established. Therefore, pet industry companies should focus on raw material quality, scientific validation, formulation design, and regulatory compliance when developing NMN products.
Guanjie Biotech is a professional bulk NMN powder supplier. We focus on innovative product research and development, along with strict quality control. Guanjie Biotech serves customers in more than 100 countries worldwide. We provide stable raw material NMN powder support and product development cooperation for pet industry clients. As the precision pet nutrition market continues to grow, NMN still offers further opportunities for exploration in dog functional nutrition.
References
[1] You Y, Gao Y, Wang H, et al. Subacute toxicity study of nicotinamide mononucleotide via oral administration[J]. Frontiers in Pharmacology, 2020, 11: 604404.
[2] Simon K E, Russell K, Mondino A, et al. A randomized, controlled clinical trial demonstrates improved cognitive function in senior dogs supplemented with a senolytic and NAD+ precursor combination[J]. bioRxiv, 2024.
[3] Guo X, Zhu C, Adam S Y, et al. Nicotinamide Mononucleotide Modulates Endothelin-1 via NR4A1 and Histone Modifications in dog Intestinal Epithelial Cells[J]. Animals, 2026, 16(4): 591.
[4] Thorsrud. (2017-2018). Toxicokinetic studies of Nicotinamide Mononucleotide (NMN) in beagle dogs (Data referenced in literature compilations)[R]. Unpublished raw data/PMC Table Citation.
[5] You Y, Gao Y, Wang H, et al. Subacute toxicity study of nicotinamide mononucleotide administered orally [J]. Frontiers in Pharmacology, 2020, 11: 604-404.
[6] Simon K E, Russell K, Mondino A, et al. Randomized controlled clinical trial of combining senescent cell scavenger with NAD+ precursor to improve cognitive function in aged dogs [J]. bioRxiv, 2024.
[7] Guo X, Zhu C, Adam S Y, et al. Regulation of endothelin-1 expression in dog intestinal epithelial cells by NR4A1 and histone modification by nicotinamide mononucleotide [J]. Animals, 2026, 16(4): 591.
[8] Thorsrud. (2017-2018). Toxicokinetic study of nicotinamide mononucleotide in beagles (PMC table cited data) [R]
